CZ Vaccines

Executive Summary

CZ Vaccines, a Spanish biopharmaceutical company and member of the Zendal Group, operates as a Contract Development and Manufacturing Organization (CDMO) specializing in vaccines and biological products for human and animal health. Founded in 2015 and headquartered in Porriño, the company leverages multiple vaccine platforms to serve multinational clients, laboratories, and governments globally. With expertise in large-scale manufacturing, CZ Vaccines is well-positioned to capitalize on the growing demand for vaccine production capacity, particularly following the COVID-19 pandemic's emphasis on rapid response capabilities. Although privately held and lacking public financial disclosures, the company's strategic role in the Zendal Group and its focus on CDMO services provide a stable revenue base and potential for growth through new client contracts and facility expansions. The company's absence from public markets limits visibility, but its specialized niche in vaccine manufacturing offers upside as global health preparedness remains a priority.

Upcoming Catalysts (preview)

• H2 2026New CDMO contract with a major pharmaceutical or biotech company for vaccine production70% success
• 2026Announcement of facility expansion or capacity upgrades to meet growing demand60% success
• 2027Client vaccine candidate achieves regulatory approval, boosting demand for CZ Vaccines' manufacturing services50% success